Method for determining the susceptibility of a NIDDM patient toward sulfonylurea therapy
OwnerPhilippe Amouyel, Nicole Helbecque +1inventors
InventorsPhilippe Amouyel, Nicole Helbecque, Aline Meirhaeghe
Life of this patent
Estimating the term…
Abstract
A method is provided for determining the susceptibility of a NIDDM patient towards sulfonylurea therapy by obtaining a sample from a NIDDM patient where the sample includes nucleic acid molecules containing a fragment of the SUR1 gene comprising the nucleotide in position −3 of exon 16 and detecting the presence or absence of the −3t allele in position −3 of exon 16 whereby the presence of at least one −3t allele identifies a NIDDM patient with a high susceptibility towards sulfonylurea therapy.
Claims12
A method for determining the susceptibility of a NIDDM patient toward sulfonylurea therapy comprising:
- a) obtaining a sample from a NIDDM patient, said sample comprising nucleic acid molecules containing the fragment of the SUR1 gene comprising the nucleotide in position −3 of exon 16,
- b) detecting the presence or the absence of the −3t allele of exon 16,
- whereby the presence of at least one −3t allele identifies a NIDDM patient with a higher susceptibility toward sulfonylurea therapy.
The method of claim 11, wherein said detecting step b) comprises obtaining a first gene fragment comprising nucleotide −3 of exon 16 isolated from said human sample and a second gene fragment comprising nucleotide −3c of exon 16, said second fragment corresponding to said first fragment, forming single-stranded DNA from said SUR1 gene fragment and from said second SUR1 gene fragment, electrophoresing said single-stranded DNAs on a denaturating polyacrylamide gel, comparing the mobility of said single-stranded DNAs on said gel to determine if said single-stranded DNA from said first SUR1 gene fragment is shifted relative to said second SUR1 gene fragment, and optionally sequencing said single-stranded DNA from said first SUR1 gene fragment having a shift in mobility.
A kit for determining the susceptibility of a NIDDM patient toward sulfonylurea therapy comprising a pair of oligonucleotide primers specific for amplifying all or part of the SUR1 gene comprising nucleotide −3 of exon 16, and instructions relating to detecting the presence of a −3t allele of exon 16 and correlating the presence of a −3t allele with a higher susceptibility toward sulfonylurea therapy.
Dependencies are inferred from the claim text.